A 31-year-old woman comes to the clinic due to a 1-year history of irregular menses and difficulty conceiving. Laboratory evaluation reveals an elevated follicle-stimulating hormone level and decreased estradiol, consistent with primary ovarian insufficiency. Her family history is significant for a maternal uncle who recently developed severe intention tremor and gait ataxia in his 60s, and a maternal cousin (son of her maternal aunt) who has intellectual disability, a long face, and macroorchidism. The physician suspects an underlying trinucleotide repeat expansion disorder. Arrange the following molecular diagnostic and management steps in the most appropriate sequential order for evaluating and managing this patient's condition.
- 1Perform targeted polymerase chain reaction (PCR) amplification of the FMR1 5' untranslated region to quantify the size of the CGG trinucleotide repeat tract.
- 2Perform Southern blot analysis to evaluate the methylation status of the FMR1 promoter and detect large full-mutation expansions that exceed PCR amplification limits.
- 3Interpret the molecular results to confirm a premutation allele (55-200 repeats), establishing the diagnosis of Fragile X-associated primary ovarian insufficiency.
- 4Counsel the patient on the risk of meiotic instability and allele expansion to a full mutation, followed by offering preimplantation genetic testing.
Cevap
The correct sequence is to first perform PCR for CGG repeat quantification, reflex to Southern blot for large expansions and methylation status, interpret the results to diagnose the premutation syndrome, and finally provide genetic counseling regarding maternal expansion risk.
The appropriate molecular evaluation of suspected Fragile X (FMR1) disorders follows a strict sequence based on the limitations of genetic testing techniques. PCR is performed first to accurately count the number of CGG repeats in the normal (<45) and premutation (55-200) ranges. Because PCR struggles to amplify very large, GC-rich full mutations (>200 repeats), Southern blot is required as a secondary step to detect massive expansions and to assess the methylation status of the FMR1 promoter (which causes gene silencing in the full mutation). Only after both tests are complete can the clinician definitively interpret the molecular status to diagnose Fragile X-associated primary ovarian insufficiency. Finally, the confirmed premutation status necessitates genetic counseling regarding anticipation, as maternal alleles are highly unstable and can expand to a full mutation during meiosis.
Adım Adım Çözüm
Anahtar Kavram
Molecular diagnosis of FMR1-related disorders requires initial sizing by PCR followed by Southern blot for methylation status, which then guides counseling on the risk of anticipation.